Description
The program will highlight the growing recognition that cumulative exposure to LDL-C drives atherosclerotic risk, making earlier and more sustained LDL-C reduction an important opportunity to alter the trajectory of disease. Dr. Bohula May will discuss how the VESALIUS-CV findings may influence patient identification, LDL-C treatment goals, therapeutic intensification, and the potential role of PCSK9 inhibitors before the first cardiovascular event occurs.Lecturer
Erin Bohula May, MD, DPhil, is a cardiovascular medicine and critical care specialist at Brigham and Women’s Hospital (BWH). In addition, she is an instructor in medicine at Harvard Medical School (HMS). She is also a staff investigator for the Thrombolysis in Myocardial Infarction (TIMI) Study Group at BWH that studies patients across the spectrum of acute coronary conditions.
Dr. Bohula May earned her medical degree from HMS. She completed a residency in internal medicine and a fellowship in cardiovascular medicine at BWH. Dr. Bohula May is board certified in internal medicine, cardiovascular disease, and critical care medicine. She was both a Rhodes Scholar and Phi Beta Kappa at HMS.
Dr. Bohula May’s clinical interests include cardiovascular critical care shock, acute coronary syndrome, stroke and metabolic cardiovascular risk factors such as dyslipidemia, diabetes and obesity. The author of 13 peer-reviewed publications, her research focuses critical care cardiology, ischemic heart disease and a randomized control trial of a weight loss agent, to assess long-term cardiovascular safety and efficacy in obese or overweight patients at high-risk for cardiovascular events.
Moderator
Ty J. Gluckman, MD, MHA, FASPC, is Medical Director of the Center for Cardiovascular Analytics, Research, and Data Science (CARDS) at the Providence Heart Institute in Portland, Oregon and an adjunct faculty member of the Ciccarone Center for the Prevention of Heart Disease at The Johns Hopkins Hospital in Baltimore, Maryland.
Dr. Gluckman’s principal clinical interests include identifying, coordinating, and implementing cardiovascular care improvement strategies. He has authored or co-authored over 50 peer-reviewed scientific articles, reviews, and book chapters. His work has been published in several high-impact journals including JACC, Circulation, JAMA, JAMA Cardiology, JAHA, and the Archives of Internal Medicine.
He serves as Associate Editor for Practice Guidelines and Clinical Documents for ACC.org, the primary web site for the American College of Cardiology (ACC). He also serves chair of the ACC Solution Set Oversight Committee. He is an active councilor and Governor-Elect for the Oregon Chapter of the ACC. He previously served as National Clinical Quality Expert for the ACC Patient Navigator Program and currently serves as National Chair of the ACC Patient Navigator Program-Focus MI. Dr. Gluckman was lead developer for the ACC/AHA Atherosclerotic Cardiovascular Disease (ASCVD) Risk Estimator app, selected as the best medical app in 2014 and more recently, helped to design the AnticoagEvaluator, BridgeAnticoag, ASCVD + and LDL-C Manager apps.
Register now
Support for this program provided by:
